NATCOPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.7
| Stock Code | NATCOPHARM | Market Cap | 15,293 Cr. | Current Price | 853 ₹ | High / Low | 1,341 ₹ |
| Stock P/E | 10.1 | Book Value | 462 ₹ | Dividend Yield | 0.70 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 865 ₹ | DMA 200 | 906 ₹ |
| Chg in FII Hold | 1.07 % | Chg in DII Hold | -0.48 % | PAT Qtr | 501 Cr. | PAT Prev Qtr | 464 Cr. |
| RSI | 49.4 | MACD | -17.1 | Volume | 6,17,824 | Avg Vol 1Wk | 4,40,834 |
| Low price | 660 ₹ | High price | 1,341 ₹ | PEG Ratio | 0.06 | Debt to equity | 0.03 |
| 52w Index | 28.4 % | Qtr Profit Var | -24.2 % | EPS | 84.8 ₹ | Industry PE | 29.2 |
📊 Analysis: NATCOPHARM shows moderate intraday potential. Current price (853 ₹) is slightly below the 50 DMA (865 ₹) and 200 DMA (906 ₹), indicating short-term weakness. RSI at 49.4 is neutral, while MACD (-17.1) signals bearish momentum. However, volume (6.17L) is higher than average (4.40L), suggesting active participation and potential volatility.
💰 Optimal Buy Price: 845 ₹ – 855 ₹ (near support zone)
📈 Profit-Taking Levels: 870 ₹ – 885 ₹
📉 Stop-Loss / Loss Protection: 835 ₹
⏱️ If Already Holding: Exit intraday if price fails to sustain above 845 ₹ or if RSI dips below 47. Consider booking profits if price approaches 870–885 ₹ with weakening momentum or volume divergence.
Positive
- Strong ROCE (31.8%) and ROE (27.5%) reflect operational efficiency.
- Low debt-to-equity ratio (0.03) indicates minimal financial risk.
- EPS of 84.8 ₹ shows solid earnings strength.
- FII holdings increased (+1.07%), reflecting foreign investor confidence.
- PEG ratio of 0.06 suggests undervaluation relative to growth.
Limitation
- Stock trading below both DMA 50 and DMA 200, showing short-term weakness.
- MACD negative (-17.1), confirming bearish momentum.
- 52-week index at 28.4% indicates weak recovery from lows.
Company Negative News
- Quarterly profit variation (-24.2%) shows earnings pressure.
- DII holdings decreased (-0.48%), reflecting reduced domestic institutional support.
Company Positive News
- PAT improved sequentially (501 Cr. vs 464 Cr.), showing resilience.
- Dividend yield of 0.70% provides steady shareholder return.
Industry
- Industry P/E at 29.2 is much higher than company’s P/E (10.1), suggesting NATCOPHARM is undervalued compared to peers.
- Pharmaceutical sector remains resilient with consistent demand and export opportunities.
Conclusion
⚖️ NATCOPHARM is a moderately good candidate for intraday trading today, supported by strong fundamentals, undervaluation, and higher-than-average volume. However, bearish technical indicators and weak 52-week recovery require cautious entries with tight stop-loss discipline. Best suited for short-term scalps with profit booking around 870–885 ₹.
Would you like me to also prepare a workflow-ready HTML template with peer benchmarking overlays (e.g., comparing NATCOPHARM with Sun Pharma, Dr. Reddy’s, and Cipla) so you can integrate sector-relative strength into your intraday reports?